Vertex Executive and Leadership Team

Gina LaCorcia, the Vice President, Chief of Staff To the Chief Executive Officer and Head of the Disease Strategy Team Program Office at Vertex, manages high-level strategic alignment between executive leadership and core research initiatives. LaCorcia directs the Disease Strategy Team Program Office, ensuring that development pipelines for cystic fibrosis and genetic disorders remain synchronized with corporate objectives. By facilitating communication across the C-suite, the Vice President optimizes decision-making processes regarding long-term therapeutic goals. This role involves translating complex scientific milestones into actionable business strategies that support the broader mission of delivering life-changing medicines. Gina LaCorcia maintains rigorous oversight of program timelines, enabling the organization to navigate the competitive biotechnology landscape with precision. Through this coordination, the Chief of Staff ensures that resource allocation aligns with the most critical unmet medical needs, ultimately driving the company toward sustainable growth and improved patient outcomes in global markets.

Charles Wagner, the Executive VP, Chief Operating Officer at Vertex, directs the global operational infrastructure required to develop and commercialize advanced biotechnology products. Wagner oversees the integration of research, manufacturing, and supply chain functions to ensure the seamless delivery of medicines for serious diseases. By architecting scalable operational frameworks, the Chief Operating Officer supports the company's ability to meet increasing global demand for cystic fibrosis and sickle cell disease therapies. This role involves close collaboration with the Board and other C-suite leaders to define long-term growth strategies and capital allocation. Charles Wagner monitors performance across all operational units, driving efficiency and ensuring compliance with international regulatory standards. Through the implementation of robust business systems, the Executive VP secures the operational stability necessary for sustained innovation. This leadership position remains central to the company's mission of transforming the lives of patients through scientific excellence and operational precision.

Arpa Garay, the Chief Operating Officer, Crinetics at Vertex, directs the operational strategy for specialized therapeutic programs within the broader corporate portfolio. Garay oversees the development and execution of business plans that support the advancement of treatments for endocrine and genetic disorders. By managing the operational lifecycle of these programs, the Chief Operating Officer ensures that research milestones are met with efficiency and precision. This role involves coordinating with cross-functional teams to optimize resource allocation and accelerate the path to commercialization. Arpa Garay monitors market dynamics and regulatory requirements, providing the strategic guidance necessary to navigate the competitive landscape. Through the implementation of robust operational processes, the Chief Operating Officer supports the company's mission of delivering innovative medicines to patients with significant unmet needs. This leadership position remains essential for driving the growth and success of specialized research initiatives within the larger biotechnology enterprise.

Amy Longwell, the Executive Assistant To Chief Human Resources Officer at Vertex, coordinates administrative operations and strategic support for the human capital division. Longwell manages complex scheduling, internal communications, and project tracking to ensure the Chief Human Resources Officer maintains focus on talent acquisition and organizational development. By streamlining workflows within the HR department, the Executive Assistant facilitates the implementation of policies that support a high-performance culture across the biotechnology enterprise. This position requires constant interaction with senior leadership to align workforce planning with the company's research and commercial goals. Amy Longwell monitors departmental performance metrics, providing the necessary data to refine recruitment and retention strategies. Through meticulous organization and proactive problem-solving, the Executive Assistant enables the HR function to scale effectively, supporting the diverse needs of the global workforce while maintaining the operational excellence required to advance innovative therapies for serious diseases.

Olivia Green, the Director, Chief of Staff, U. S. Commercial at Vertex, oversees the operational execution of commercial strategies within the United States market. Green directs cross-functional teams to ensure the successful delivery of therapies for cystic fibrosis and other genetic conditions to healthcare providers and specialty pharmacies. By managing the internal rhythm of the U.S. commercial organization, the Director aligns sales and marketing efforts with broader corporate objectives. This role involves analyzing market trends and competitive dynamics to refine regional distribution strategies. Olivia Green facilitates communication between field teams and executive leadership, ensuring that operational challenges receive immediate attention. Through the optimization of commercial processes, the Chief of Staff supports the expansion of patient access to critical treatments. This leadership function remains essential for maintaining market leadership and ensuring that the company's innovative portfolio reaches the patients who require these specialized medical solutions.

Katie Noon, the Chief of Staff & Director at Vertex, manages strategic initiatives and organizational alignment across key business units. Noon directs the execution of high-priority projects that support the company's research and development pipeline for genetic disorders. By facilitating cross-departmental collaboration, the Chief of Staff ensures that operational goals remain consistent with the overarching mission of delivering transformative therapies. This role involves synthesizing complex information for executive review, enabling informed decision-making regarding resource allocation and market strategy. Katie Noon monitors the progress of critical programs, identifying potential bottlenecks and implementing solutions to maintain momentum. Through the coordination of internal resources, the Director supports the company's ability to address significant unmet medical needs. This leadership function provides the structural support necessary for the organization to navigate the complexities of the biotechnology industry while maintaining a focus on long-term scientific and commercial success.

Stephanie Franklin, the Senior Vice President and Chief Human Resources Officer, Vertex Pharmaceuticals at Vertex, leads the global strategy for talent management, organizational culture, and leadership development. Franklin directs the human resources function to ensure the company attracts and retains the specialized expertise required for cutting-edge biotechnology research. By implementing comprehensive workforce programs, the Chief Human Resources Officer fosters an environment of innovation and scientific excellence. This role involves partnering with the executive team to align human capital strategies with the company's long-term growth objectives in the pharmaceutical sector. Stephanie Franklin oversees the design of compensation, benefits, and professional development initiatives that support a diverse and high-performing workforce. Through the cultivation of a strong organizational culture, the Senior Vice President ensures that the company remains well-positioned to address complex genetic disorders. This leadership role remains vital for maintaining the operational capacity needed to deliver life-changing medicines to patients worldwide.

Whitney Miller, the Chief of Staff & Director & Senior VP, Commercial Manufacturing & Technical Operations at Vertex, directs the technical and manufacturing processes required to produce complex therapeutic products. Miller oversees the scaling of manufacturing capabilities to ensure a reliable supply of medicines for patients with serious diseases. By managing the intersection of technical operations and commercial strategy, the Senior VP ensures that production timelines align with market launch requirements and ongoing patient needs. This role involves coordinating with quality and regulatory teams to maintain the highest standards of product integrity. Whitney Miller facilitates the implementation of advanced manufacturing technologies that improve efficiency and reduce time-to-market for new therapies. Through the oversight of technical operations, the Chief of Staff ensures that the company's manufacturing footprint supports global distribution goals. This leadership position remains essential for maintaining the supply chain resilience necessary to deliver innovative treatments to patients across diverse international markets.

Colleen O'Brien, the Toxicology Research Senior Scientist & Chief Revenue Officer, Study Monitor at Vertex, manages the intersection of scientific research and revenue generation strategies. O'Brien directs toxicology studies to ensure the safety and efficacy of new drug candidates, while simultaneously overseeing revenue optimization for existing therapeutic portfolios. By monitoring clinical study data, the Chief Revenue Officer provides critical insights that inform commercial pricing and market access strategies. This role involves balancing the rigorous demands of scientific validation with the financial objectives of the company. Colleen O'Brien coordinates with research teams to accelerate the development of therapies for genetic disorders, ensuring that commercial viability remains a key consideration throughout the research lifecycle. Through the integration of scientific expertise and financial oversight, the Senior Scientist drives the company's ability to fund future innovation. This unique leadership function ensures that the organization maintains a sustainable balance between scientific discovery and commercial success.

Dionna Di Pierro, the Senior Director, Chief of Staff To the Senior Vice President of Quality at Vertex, manages the strategic operations of the quality assurance and regulatory compliance functions. Di Pierro directs the internal processes that ensure all manufacturing and research activities adhere to the highest global standards of safety and efficacy. By facilitating communication between the quality department and other executive functions, the Chief of Staff ensures that compliance remains a core component of the company's operational strategy. This role involves overseeing the implementation of quality management systems that support the development of therapies for serious diseases. Dionna Di Pierro monitors regulatory trends and internal performance metrics, providing the Senior Vice President of Quality with the data necessary to mitigate risks and maintain operational excellence. Through the coordination of quality initiatives, the Senior Director supports the company's ability to deliver reliable and safe medicines to patients worldwide, ensuring long-term trust and market success.